Kitaya Kotaro, Ishikawa Tomomoto
Reproduction Clinic Osaka, Grand Front Osaka Tower-A 15F, 4-20 Oofuka-cho, Kita-ku, Osaka, 530-0011, Japan.
Arch Gynecol Obstet. 2022 Nov;306(5):1761-1769. doi: 10.1007/s00404-022-06755-2. Epub 2022 Aug 21.
We prospectively investigated if oral enteric coating lactoferrin supplementation improves the reproductive outcomes in infertile women with a history of repeated implantation failure (RIF) and non-Lactobacillus-dominant (Lactobacillus rate < 90%) microbiota (NLDM) in vaginal secretions (VS)/endometrial fluid (EF).
Paired VS/EF samples were obtained from RIF women and control infertile women (non-RIF group) for microbiome analysis. Chronic endometritis (CE) was diagnosed histopathologically and hysteroscopically. In a pilot study, oral enteric coating lactoferrin (700 mg/day, at least 28 consecutive days) was administered to eligible patients with NLDM in VS/EF. Their reproductive outcomes in the subsequent vitrified-warmed embryo transfer cycles were followed up.
While CE was more prevalent (OR 2.41, 95% CI 1.02-5.63, p = 0.042) in the RIF group (29.1%, n = 117) than in the non-RIF group (14.5%, n = 55), The NLDM rate was similar between the two groups (44.4 vs 52.7%). Lactoferrin supplementation improved NLDM in 43.2% of RIF women (n = 37). Within the RIF group, the live birth rate in the subsequent cycles was higher (OR 10.67, 95% CI 1.03 - 110.0, p = 0.046) in women with improved microbiota (57.1%, n = 14) than in those with unimproved microbiota (11.1%, n = 9).
Unlike CE, NLDM was not unique to RIF but was common in infertile women. Although the therapeutic effect of the oral lactoferrin supplementation on NLDM was limited in a pilot study, the reproductive outcomes were better in RIF women who overcame NLDM than in those who failed. Randomized controlled trials are required to confirm the results. TRIAL REGISTRATION NUMBER AND DATE FOR PROSPECTIVELY REGISTERED TRIALS: UMIN-CTR 000036990, June 7, 2019.
我们前瞻性研究了口服肠溶乳铁蛋白补充剂是否能改善有反复种植失败(RIF)病史且阴道分泌物(VS)/子宫内膜液(EF)中微生物群非乳酸杆菌占优势(乳酸杆菌率<90%,即NLDM)的不孕女性的生殖结局。
从RIF女性和对照不孕女性(非RIF组)获取配对的VS/EF样本进行微生物组分析。通过组织病理学和宫腔镜检查诊断慢性子宫内膜炎(CE)。在一项初步研究中,对VS/EF中存在NLDM的符合条件的患者给予口服肠溶乳铁蛋白(700毫克/天,至少连续28天)。对她们在随后的玻璃化冷冻胚胎移植周期中的生殖结局进行随访。
虽然RIF组(29.1%,n = 117)中CE的患病率高于非RIF组(14.5%,n = 55)(OR 2.41,95% CI 1.02 - 5.63,p = 0.042),但两组的NLDM率相似(44.4%对52.7%)。补充乳铁蛋白使43.2%的RIF女性(n = 37)的NLDM得到改善。在RIF组中,微生物群改善的女性(57.1%,n = 14)在随后周期中的活产率高于微生物群未改善的女性(11.1%,n = 9)(OR 10.67,95% CI 1.03 - 110.0,p = 0.046)。
与CE不同,NLDM并非RIF所特有,而是在不孕女性中常见。虽然在一项初步研究中口服乳铁蛋白补充剂对NLDM的治疗效果有限,但克服NLDM的RIF女性的生殖结局优于未克服的女性。需要进行随机对照试验来证实结果。前瞻性注册试验的试验注册号和日期:UMIN - CTR 000036990,2019年6月7日。